Canaccord Reiterates Rating On CloudMD After Quarterly Results

On August 25, CloudMD Software & Services (TSXV: DOC) reported their second quarter financial results. The company announced record revenues of $15.7 million, up 461% year over year. Gross profit came in at $5.55 million, up 439% and gross margin was 35.5%. The company lost $6.15 million on the bottom line, resulting in earnings per share of ($0.03.) Adjusted EBITDA meanwhile came in at ($0.72) million.

CloudMD currently has 6 analysts covering the stock with an average 12-month price target of $3.97, or an 112% upside. The street high sits at $5.00 from Stephens Inc, while the lowest comes in at $3.30. Out of the 6 analysts, 2 have strong buy ratings and 4 have buy ratings.

In Canaccord’s note to investors, they reiterated their $3.50 12-month price target and speculative buy rating saying that this quarter showed organic growth and that they expect profits in the third quarter.

CloudMD reported $15.7 million in revenue, higher than the Canaccord $15.3 million estimate and $15.0 million street estimate. Adjusted EBITDA also came in better than expected. Canaccord says that revenue benefitted from partial contributions from its Aspiria, Rx Infinity, VisionPros, and Ocdidium deals closing in the middle of the quarter.

Canaccord says that the company’s 9% sequential organic growth is notable as the company has been in roll-up mode for a long time, so it was hard to get accurate organic growth data. Canaccord adds, “The company has a strong sales pipeline of multi-year engagement opportunities, expecting two additional employers to go live in Q3.” Canaccord does believe that the company has enough cash to execute on any new M&A that comes up, as the company ended the quarter with $61 million in cash, $25 million in debt and $62 million in a credit facility.

Below you can see Canaccord’s updated third quarter, full-year 2021, and 2022 estimates. They have modified their estimates as they expect a more conservative ramp into profitability.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

First Majestic Posts Record Cash Flows In Q1 As Production Costs Fall

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Related News

Equinox: BMO Lowers Price Target To $14.50 Follow Mercedes Mine Sale

On December 17th, Equinox Gold (TSX: EQX) announced that they reached an agreement to sell...

Tuesday, December 28, 2021, 11:06:00 AM

Haywood Lifts Filo Mining’s Price Target After Strong Assay Results

On May 23, Filo Mining (TSX: FIL) reported its assay results from holes FSDH055C and...

Sunday, May 29, 2022, 03:05:00 PM

Canaccord Resumes Coverage On The Valens Company, Issues $6.50 Price Target

This morning Canaccord Genuity resumed coverage on The Valens Company (TSX: VLNS) with a C$6.50...

Monday, July 6, 2020, 10:57:25 AM

Harvest Health: Canaccord, Stifel Raise Price Targets

Earlier this week, Harvest Health & Recreation (CSE: HARV) released its third quarter results. The...

Thursday, November 12, 2020, 03:57:03 PM

Canaccord Raises Mind Medicine’s Price Target To $2.00 Following Financing

This morning, Canaccord Genuity raised its 12-month price target on Mind Medicine (NEO: MMED) from...

Monday, November 2, 2020, 10:45:02 AM